---
schema_version: "secwatch.filing_event.v1"
accession: "0001759425-24-000017"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:05:09.612186+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mirum Q1 revenue $69.2M, up 119% YoY; reaffirms FY guidance $310-320M

## Summary
- Global product sales net $68.9M, up 137% vs Q1 2023; LIVMARLI net sales $42.8M (+47%).
- FDA approved LIVMARLI for PFIC cholestatic pruritus in March 2024.
- Volixibat interim analyses (VISTAS/VANTAGE) expected June 2024; CHENODAL NDA for CTX on track H1 2024.
- Cash and equivalents $302.8M as of March 31, 2024, up from $286.3M at year-end 2023.
- Operating expenses $95.7M (incl. $17.1M non-cash items) vs $58.7M in prior-year quarter.

## SEC filing metadata
- accession: 0001759425-24-000017
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000175942524000017/0001759425-24-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000175942524000017/mirm-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759425-24-000017
- JSON: https://secwatch.observer/filing/0001759425-24-000017.json
- Plain text: https://secwatch.observer/filing/0001759425-24-000017.txt

## Key facts
- Earnings Releases
  Mirum Pharmaceuticals, Inc. reported the quarter ended March 31, 2024 results: revenue $69.2 million. Guidance reaffirmed.
  - Period: the quarter ended March 31, 2024
  - Revenue: $69.2 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: such filing. --- EX-99.1 (EX-99.1) --- Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update • First quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million • FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients achieved in March • Volixibat VISTAS and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000175942524000017/0001759425-24-000017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.